Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01034865 · ClinicalTrials.gov registry record
Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 750
- Enrollment target
NCT01034865: Completed study, sponsored by Stanford University.
NCT01034865 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 750 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01034865 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
Study Summary
To identify risk factors for the development and diagnosis of hepatocellular CA in patients with chronic hepatitis C and to use the data to ultimately develop an effective screening program.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2001-05 |
| Est. Completion | 2009-06 |
What the finished NCT01034865 record still lists
NCT01034865 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01034865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01034865 about?
NCT01034865 is a clinical study titled "Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer". To identify risk factors for the development and diagnosis of hepatocellular CA in patients with chronic hepatitis C and to use the data to ultimately develop an effective screening program.
What is the current status of trial NCT01034865?
This trial is currently completed. The enrollment target is 750 participants. The study started on 2001-05. Estimated completion is 2009-06.
Who is sponsoring clinical trial NCT01034865?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia